Design and Evaluation of Endosomolytic Biocompatible Peptides as Carriers for siRNA Delivery

详细信息    查看全文

• 作者：Wen Xu ; Ran Pan ; Danyang Zhao ; Dafeng Chu ; Yan Wu ; Rong Wang ; Baoling Chen ; Yong Ding ; Parisa Sadatmousavi ; Yongfang Yuan ; P. Chen
• 刊名：Molecular Pharmaceutics
• 出版年：2015
• 出版时间：January 5, 2015
• 年：2015
• 卷：12
• 期：1
• 页码：56-65
• 全文大小：452K
• ISSN：1543-8392

文摘

Gene therapy using RNA interference (RNAi) technology has been explored to treat cancers, by regulating the expression of oncogene. However, even though small interfering RNA (siRNA), which triggers RNAi, may have great therapeutic potential, efforts at using them in vivo have been hampered by the difficulty of effective and safe delivery into cells of interest. In this study, to develop a safe and efficient carrier for in vitro and in vivo siRNA delivery, we designed a peptide library. These peptides are improved variants of a known peptide based siRNA carrier C6. All the modifications improved the transfection efficiency of C6 to some degree. After completing prescreening for activity, several promising candidates were used for further evaluation. Selected peptides C6M3 and C6M6 could form stable complexes with siRNA. These complexes could be greatly uptaken by cells and showed a punctate perinuclear distribution. Moreover, peptide/siRNA complexes achieved high transfection efficiency in vitro without inducing substantial cytotoxicity. We have validated the therapeutic potential of this strategy for cancer treatment by targeting Bcl-2 gene in mouse tumor models, and demonstrated that tumor growth was inhibited. In order to address possible immune side effects of these peptide carriers, biocompatibility study in terms of complement activation and cytokine activation assay were carried out, whereas none of the peptides induced such effects. In conclusion, these results support the potential of these peptides as therapeutic siRNA carrier.